Clinical Research Directory

Inclusion Criteria: * Patient with bone pain related to at least 1 or more bone metastases of spinal location, contiguous or not, cervical (excluding C1), thoracic, lumbar or sacral up to and including S2; a patient can be included even if he or she is irradiated concomitantly or not for analgesic purposes on another non-spinal bone metastatic site. Bone lesions are objective on an imaging examination less than 3 months old: CT and/or MRI and/or PET and/or bone scintigraphy; * Patient with at least moderate pain with EN ≥ 5; * Patient on analgesic drug treatment for at least 7 days or poor tolerance of analgesics; * Patient irradiated for palliative analgesic purposes. Post-cementoplasty irradiation is possible; an extension to the soft tissues is not a contraindication to inclusion; * Patient with a validated palliative bone irradiation plan: 8 Gy / 1 fr or 20 Gy / 5 fr; * Patient with planning only in static IMRT, arc therapy or helical tomotherapy; * Patient with a primary cancer or a haemopathy; * Patient currently undergoing or not a specific oncological systemic treatment, left to the discretion of the investigating physician; * Patient currently undergoing or not a treatment with bisphosphonates and denosumab, left to the discretion of the investigating physician; * WHO ≤ 2; * Patient with a life expectancy ≥ 3 months; * Patient able and agreeing to follow all study procedures in accordance with the protocol; * Patient having understood, signed and dated the consent form; * Patient affiliated to the social security system. Exclusion Criteria: * Pediatric patient; * Patient undergoing stereotaxic irradiation; * Patient undergoing oligometastatic disease; * Patient undergoing re-irradiation unless the dose is not limiting to OARs; * Patient treated with RT2D (conventional 2-dimensional radiotherapy) or RT3D (conventional 3-dimensional radiotherapy); * Patient with MESCC (metastatic epidural spinal cord compression) except for a Bilsky grade \< 1b; * Patient who does not have a means of responding to online questionnaires; * Patient and their entourage who cannot read or express themselves in French; * Visually impaired patient; * Patient already included in another therapeutic trial with an experimental molecule; * Persons deprived of liberty or under guardianship (including curatorship). * Pregnant woman, likely to be pregnant, or breastfeeding